Drug Trial Radar · NCT00150735
Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy
Last checked: Nov 20, 2026Latest source record: Nov 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
580
Actual
Start
Jun 2002
Primary completion
Jul 2005
Study completion Jul 2005
Sponsor
- Lead sponsor
- UCB PharmaUCB
- Sponsor type
- Industry
- First posted
- Sep 8, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- All sexes, from 16 years
Summary
As written by the sponsor on the registry.
A double-blind trial comparing the efficacy and safety of levetiracetam to carbamazepine used as monotherapy in subjects (≥ 16 years) newly or recently diagnosed as suffering from epilepsy, and experiencing partial or generalized tonic-clonic seizures.
Conditions
- Generalized Epilepsy
Interventions
LEVETIRACETAMDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate that levetiracetam monotherapy is not inferior to carbamazepine by measuring the proportion of subjects with 6-month seizure freedom in subjects newly diagnosed as suffering from epilepsy.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.